This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Dose-response Study of Exendin-9,39 on Glucose Metabolism

This study has been completed.
Information provided by (Responsible Party):
Adrian Vella, Mayo Clinic Identifier:
First received: October 8, 2010
Last updated: January 18, 2013
Last verified: January 2013
Multiple studies have examined the effect of endogenous GLP-1 secretions by using a competitive antagonist of GLP-1 - Exendin-9,39 - infused at rates of 300pmol/kg/min. However, the presence of an effect does not necessarily imply that this effect is due to the blockade of the endogenous GLP-1 actions at the receptor. It is possible that the supraphysiologic concentrations of Exendin may have effects of its own. To examine the effect of Exendin on glucose metabolism the investigators propose a dose-response study to determine whether the compound has effects in a dose-dependent fashion.

Condition Intervention Phase
Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1 Drug: saline infusion Drug: GLP-1-9,36 infusion Drug: Exendin-9,39 at low dose Drug: Exendin-9,39 at high dose Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: A Dose-response Study of the Effects of Exendin-9,39 on Glucose Metabolism, Glucagon and Insulin Secretion and on Insulin Action.

Further study details as provided by Adrian Vella, Mayo Clinic:

Primary Outcome Measures:
  • Insulin Secretion [ Time Frame: over 360 minutes of study ]

Secondary Outcome Measures:
  • glucagon secretion [ Time Frame: over 360 minutes of study ]

Enrollment: 11
Study Start Date: May 2011
Study Completion Date: December 2012
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Saline Drug: saline infusion
saline infused at 30ml/hour
Active Comparator: GLP-1-(9,36)-amide Drug: GLP-1-9,36 infusion
infused @ 1.2pmol/kg/min
Active Comparator: Exendin-9,39 @30pmol/kg/min Drug: Exendin-9,39 at low dose
infused at 30pmol/kg/min
Active Comparator: Exendin-9,39 @300pmol/kg/min Drug: Exendin-9,39 at high dose
infused @ 300pmol/kg/min


Ages Eligible for Study:   20 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Healthy Not on any medication other than thyroid hormone replacement or OCP No history of diabetes No prior upper GI surgery
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01218633

United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Adrian Vella
Principal Investigator: Adrian Vella, MD Mayo Clinic
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Adrian Vella, Professor of Medicine, Mayo Clinic Identifier: NCT01218633     History of Changes
Other Study ID Numbers: 10-003435
Study First Received: October 8, 2010
Last Updated: January 18, 2013 processed this record on June 22, 2017